Research Papers:

Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer

Chen-Hung Ting _, Yi-Chun Chen, Chang-Jer Wu and Jyh-Yih Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:40329-40347. https://doi.org/10.18632/oncotarget.9612

Metrics: PDF 1781 views  |   HTML 1461 views  |   ?  


Chen-Hung Ting1, Yi-Chun Chen1, Chang-Jer Wu2, Jyh-Yih Chen1

1Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, Jiaushi, Ilan 262, Taiwan

2Department of Food Science, National Taiwan Ocean University, Keelung 202, Taiwan

Correspondence to:

Jyh-Yih Chen, email: zoocjy@gate.sinica.edu.tw

Keywords: TP4, cationic antimicrobial peptide, triple-negative breast cancer, calcium, FOSB

Received: February 12, 2016    Accepted: May 02, 2016    Published: May 26, 2016


Triple-negative breast cancer (TNBC) currently lacks a suitable therapeutic candidate and is thus difficult to treat. Here, we report that a cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which was derived from Nile tilapia (Oreochromis niloticus), is selectively toxic to TNBC. TP4 acts by inducing an AP-1 protein called FOSB, the expression of which is negatively associated with the pathological grade of TNBC. We show that TP4 is bound to the mitochondria where it disrupts calcium homeostasis and activates FOSB. FOSB overexpression results in TNBC cell death, whereas inhibition of calcium signaling eliminates FOSB induction and blocks TP4-induced TNBC cell death. Both TP4 and anthracyclines strongly induced FOSB, particularly in TNBC, indicating that FOSB may be suitable as a biomarker of drug responses. This study thus provides a novel therapeutic approach toward TNBC through FOSB induction.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9612